David, Rimm, MD, PhD, FCAP, comments in regards to using immunohistochemistry tests to quantify low levels of HER2 "is like weighing mice on a scale built for elephants,” states Dr. Rimm
For the full article click here: Patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement, experts say